Evidence map›Paper›PMID 24516629›Full record

ArticlePloS one2014

The neurogenic effects of exogenous neuropeptide Y: early molecular events and long-lasting effects in the hippocampus of trimethyltin-treated rats.

Valentina Corvino, Elisa Marchese, Maria Vittoria Podda, Wanda Lattanzi, Stefano Giannetti, Valentina Di Maria, Sara Cocco, Claudio Grassi, Fabrizio Michetti, Maria Concetta Geloso

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Valentina CorvinoInstitute of Anatomy and Cell Biology - Università Cattolica del Sacro Cuore, Rome, Italy.
Elisa MarcheseInstitute of Anatomy and Cell Biology - Università Cattolica del Sacro Cuore, Rome, Italy.
Maria Vittoria PoddaInstitute of Human Physiology - Università Cattolica del Sacro Cuore, Rome, Italy.
Wanda LattanziInstitute of Anatomy and Cell Biology - Università Cattolica del Sacro Cuore, Rome, Italy.
Stefano GiannettiInstitute of Anatomy and Cell Biology - Università Cattolica del Sacro Cuore, Rome, Italy.
Valentina Di MariaInstitute of Anatomy and Cell Biology - Università Cattolica del Sacro Cuore, Rome, Italy.
Sara CoccoInstitute of Human Physiology - Università Cattolica del Sacro Cuore, Rome, Italy.
Claudio GrassiInstitute of Human Physiology - Università Cattolica del Sacro Cuore, Rome, Italy.
Fabrizio MichettiInstitute of Anatomy and Cell Biology - Università Cattolica del Sacro Cuore, Rome, Italy.
Maria Concetta GelosoInstitute of Anatomy and Cell Biology - Università Cattolica del Sacro Cuore, Rome, Italy.
Università Cattolica del Sacro Cuore · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Modulation of endogenous neurogenesis is regarded as a promising challenge in neuroprotection. In the rat model of hippocampal neurodegeneration obtained by Trimethyltin (TMT) administration (8 mg/kg), characterised by selective pyramidal cell loss, enhanced neurogenesis, seizures and cognitive impairment, we previously demonstrated a proliferative role of exogenous neuropeptide Y (NPY), on dentate progenitors in the early phases of neurodegeneration. To investigate the functional integration of newly-born neurons, here we studied in adult rats the long-term effects of intracerebroventricular administration of NPY (2 µg/2 µl, 4 days after TMT-treatment), which plays an adjuvant role in neurodegeneration and epilepsy. Our results indicate that 30 days after NPY administration the number of new neurons was still higher in TMT+NPY-treated rats than in control+saline group. As a functional correlate of the integration of new neurons into the hippocampal network, long-term potentiation recorded in Dentate Gyrus (DG) in the absence of GABAA receptor blockade was higher in the TMT+NPY-treated group than in all other groups. Furthermore, qPCR analysis of Kruppel-like factor 9, a transcription factor essential for late-phase maturation of neurons in the DG, and of the cyclin-dependent kinase 5, critically involved in the maturation and dendrite extension of newly-born neurons, revealed a significant up-regulation of both genes in TMT+NPY-treated rats compared with all other groups. To explore the early molecular events activated by NPY administration, the Sonic Hedgehog (Shh) signalling pathway, which participates in the maintenance of the neurogenic hippocampal niche, was evaluated by qPCR 1, 3 and 5 days after NPY-treatment. An early significant up-regulation of Shh expression was detected in TMT+NPY-treated rats compared with all other groups, associated with a modulation of downstream genes. Our data indicate that the neurogenic effect of NPY administration during TMT-induced neurodegeneration involves early Shh pathway activation and results in a functional integration of newly-generated neurons into the local circuit.

Indexed as

AnimalsFemaleHedgehog ProteinsHippocampusKruppel-Like Transcription FactorsLong-Term PotentiationNeurogenesisNeuropeptide YNeuroprotective AgentsPyramidal CellsRatsRats, WistarSignal TransductionTrimethyltin CompoundsHedgehog ProteinsKlf9 protein, ratKruppel-Like Transcription FactorsNeuropeptide YNeuroprotective AgentstrimethyltinTrimethyltin Compounds

Identifiers

PMID24516629
PMCPMC3917853
OpenAlexW2001978957

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.